Clinical Trials in France / NCT06924463
Recruiting
Observational
Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdomyosarcoma Through Spatial Proteome Analysis Using Mass Spectrometry
NCT06924463 · tracked via the Priya Life Science France tracker
Condition(s) studied
Rhabdomyosarcoma
Investigational drug(s) / intervention(s)
None AHT
None AHT: This study does not involve any interventions. It analyzes pre-existing biological samples (FFPE tumor tissue) and clinical data from patients with rhabdomyosarcoma.
Study summary
This non-interventional study aims to develop spatial proteomics for analyzing small FFPE tumor samples in rhabdomyosarcoma. It will identify molecular signatures linked to tumor regions, subtypes, survival, and treatment resistance, using pre-existing samples and data.
Eligibility
Inclusion Criteria:
* Age between 0 and 25 years at the time of initial diagnosis
* Diagnosis of rhabdomyosarcoma confirmed histologically
* Care at the Oscar Lambret Center between January 2005 and November 2024
* No objection to the re-use of data and biological samples collected as part of care for research activities.
Exclusion Criteria:
* Unavailability of biological sample in FFPE from biopsy and/or surgical specimen for diagnosis at Centre Oscar Lambret;
* Patient under guardianship or trusteeship.
Primary outcome measure(s)
- Spatial Proteomic Profiling of Tumor Samples — 12 months (study duration)
Evaluate the ability to obtain distinct proteomic profiles from at least 75% of tumor samples analyzed, with a minimum of two distinct profiles identified per sample.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Oscar Lambret Center | Lille | Nord | Recruiting |
More Lille University trials in France
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06924463 on ClinicalTrials.gov ↗ ← All trials in France